Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03946085 · ClinicalTrials.gov registry record · NA

Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)

A NA study of Age-related Macular Degeneration and Macular Degeneration, sponsored by Guardion Health Sciences.

Completed
Registry status
NA
Development phase
79
Enrollment target
1
Study location

NCT03946085 is a NA study of Age-related Macular Degeneration and Macular Degeneration that has completed, run by Guardion Health Sciences. The registered enrollment target is 79 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03946085, a NA study of Age-related Macular Degeneration and Macular Degeneration, has completed, sponsored by Guardion Health Sciences.

COMPLETED
Registry status
NA
Development phase
79 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to evaluate the clinical benefits in visual function from dietary supplementation of the Lumega-Z carotenoid liquid-supplement in participants with drusen and at risk of AMD. The effects of Lumega-Z supplementation will be compared to an active comparator, the AREDS2 multivitamin.

Interventions

  • DIETARY_SUPPLEMENT Lumega-Z
  • DIETARY_SUPPLEMENT AREDS2

Study Locations (1)

Texas

  • Eye Clinic of Austin - Austin

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2018-01-19
Est. Completion 2018-11-01
Phase NA

Sponsor

Guardion Health Sciences

1 total trials

What the Registry Record Tells You About NCT03946085

The ClinicalTrials.gov registry entry for NCT03946085 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The listed sponsor is Guardion Health Sciences, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Lumega-Z is the first listed.

NCT03946085 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03946085 about?

NCT03946085 is a clinical study titled "Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)". The aim of this study is to evaluate the clinical benefits in visual function from dietary supplementation of the Lumega-Z carotenoid liquid-supplement in participants with drusen and at risk of AMD. The effects of Lumega-Z supplementation will be compared to an active comparator, the AREDS2 multivi...

What is the current status of trial NCT03946085?

This trial is currently completed. It is a NA study. The enrollment target is 79 participants. The study started on 2018-01-19. Estimated completion is 2018-11-01.

What conditions does trial NCT03946085 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Macular Degeneration, Retinal Drusen.

What interventions are being tested in trial NCT03946085?

The interventions under investigation include: Lumega-Z (DIETARY_SUPPLEMENT), AREDS2 (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03946085?

This trial is sponsored by Guardion Health Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03946085 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.